MingMed Biotechnology Announces IND Clearance for HPK1 Inhibitor PRJ1-3024 and Completion of Phase I Dosing for Dry AMD Drug QA102 in the U.S.

Investment Circle (ID: pedaily2012) November 19th news, Guangzhou MingMed Biotechnology Co., Ltd. (MingMed Biotechnology, hereinafter referred to as "MingMed") announced that its First-in-Class HPK1 small molecule inhibitor PRJ1-3024 for cancer immunotherapy has passed the IND of the US FDA.ProcedureMingMed simultaneously announced that its First-in-Class ophthalmic new drug QA102 for Dry Age-Related Macular Degeneration (Dry AMD) being conducted in the United States has successfully completed dosing for all subjects in the Phase I clinical trial.

MingMed was founded in November 2019, with a research and development team composed of several top scientists and experts, as well as a scientific committee made up of globally influential scientists.Ophthalmic drugs, novel medical aesthetics drugs, small-molecule immunotherapeutics, and cell therapyMore than a dozen products are under development in various fields, the vast majority of which are competitive, breakthrough First-in-Class innovative drugs. Moreover, the main products have generally completed the early-stage research and development or have already been commercialized.

Professor Xuebin Liao, Professor at the School of Pharmaceutical Sciences, Tsinghua University, and Director of MingMedHPK1 is an important target in tumor immunology. Targeting HPK1 can effectively regulate several key types of immune cells, activating their synergistic anti-tumor effects. MingMed has a solid scientific foundation in the mechanism of the HPK1 target. PRJ1-3024, a product fully independently developed by MingMed, is in the global first-tier and boasts a series of advantages such as better selectivity. PRJ1-3024 passing the U.S. clinical trial application marks MingMed's official entry into the competition in the billion-dollar field of innovative tumor immunotherapy drugs. We will accelerate clinical research in the hope of benefiting cancer patients worldwide more quickly.

MingMed CEO Zhang YanQA102, which targets dry age-related macular degeneration—an untreatable blinding eye disease globally—shows enormous clinical demand and market potential. The Phase I clinical trial of QA102 conducted in the U.S. has been successfully completed, and it is about to enter the Phase II clinical trial stage. This will fill the gap for a First-in-Class ophthalmic innovative drug developed by a Chinese team entering global Phase II clinical trials. The progress achieved by PRJ1-3024 and QA102 demonstrates that MingMed possesses the scientific strength to achieve significant breakthroughs in multiple areas of pharmaceutical innovation, as well as the operational capability to efficiently advance the development of multiple product pipelines. We will continue our efforts to contribute to human health.